Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

ROSWELL PARK CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

Phase 1

Suspended

Conditions: Recurrent Transformed Chronic Lymphocytic Leukemia
Refractory Diffuse Large B-Cell Lymphoma
Refractory High Grade B-Cell Lymphoma
Refractory Mantle Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent High Grade B-Cell Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Follicular Lymphoma
Refractory Chronic Lymphocytic Leukemia
Refractory Follicular Lymphoma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Procedure: Echocardiography
Drug: Cyclophosphamide
Biological: EGFRt/19-28z/IL-12 CAR T-lymphocytes
Procedure: Multigated Acquisition Scan
Drug: Fludarabine Phosphate
Procedure: Leukapheresis
Procedure: Positron Emission Tomography

First Posted Date: 2024-04-02

Last Posted Date: 2025-03-07

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 54

Registration Number: NCT06343376

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream

Early Phase 1

Not yet recruiting

Conditions: Cannabis Dependence

Interventions: Procedure: Biospecimen Collection
Drug: Cannabis sativa Extract
Drug: Nicotine
Drug: Placebo Administration
Other: Questionnaire Administration

First Posted Date: 2024-03-27

Last Posted Date: 2025-06-11

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 60

Registration Number: NCT06334016

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

MedSupport Intervention to Identify and Address Barriers to Pediatric Medication Adherence

Not Applicable

Recruiting

Conditions: Acute Lymphoblastic Leukemia

Interventions: Procedure: Biospecimen Collection
Other: Best Practice
Other: Electronic Health Record Review
Other: Interview
Other: Medical Device Usage and Evaluation
Other: Survey Administration

First Posted Date: 2024-03-21

Last Posted Date: 2025-03-20

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 150

Registration Number: NCT06323044

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma

Recruiting

Conditions: Pancreatic Ductal Adenocarcinoma

Interventions: Other: Blood sample

First Posted Date: 2024-03-20

Last Posted Date: 2025-04-25

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 100

Registration Number: NCT06320717

Locations: 🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
🇺🇸
Good Samaritan University Hospital, West Islip, New York, United States

Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer

Phase 1

Recruiting

Conditions: Stage III Colorectal Cancer
Locally Advanced Colorectal Carcinoma
Recurrent Colorectal Carcinoma

Interventions: Drug: Aminolevulinic Acid
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Fluorescence-Guided Surgery
Procedure: Magnetic Resonance Imaging
Drug: Photodynamic Therapy
Procedure: Surgical Procedure

First Posted Date: 2024-03-13

Last Posted Date: 2024-08-05

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 21

Registration Number: NCT06307548

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

Phase 1

Recruiting

Conditions: Castration-Resistant Prostate Carcinoma
Metastatic Prostate Carcinoma
Stage IVB Prostate Cancer AJCC v8

Interventions: Procedure: Biopsy
Procedure: Bone Scan
Procedure: Computed Tomography
Drug: Leuprolide Acetate
Procedure: Magnetic Resonance Imaging
Other: Survey Administration
Drug: Testosterone Cypionate

First Posted Date: 2024-03-12

Last Posted Date: 2025-01-17

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 14

Registration Number: NCT06305598

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction

Phase 1

Recruiting

Conditions: Malignant Solid Neoplasm

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Endobronchial Ultrasound Bronchoscopy
Procedure: Interstitial Photodynamic Therapy
Other: Physical Performance Testing
Radiation: Palliative Radiation Therapy
Other: Questionnaire Administration
Drug: Verteporfin

First Posted Date: 2024-03-12

Last Posted Date: 2025-01-20

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 39

Registration Number: NCT06306638

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Implementation of Evidence-Based Strategy (PC TEACH) for the Optimization of HPV Vaccination in Rural Primary Care

Not Applicable

Recruiting

Conditions: Human Papillomavirus Infection

Interventions: Other: Educational Intervention

First Posted Date: 2024-02-13

Last Posted Date: 2025-03-10

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 560

Registration Number: NCT06256718

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma

Phase 1

Withdrawn

Conditions: Advanced Pancreatic Ductal Adenocarcinoma
Locally Advanced Pancreatic Ductal Adenocarcinoma
Metastatic Pancreatic Ductal Adenocarcinoma
Refractory Pancreatic Ductal Adenocarcinoma
Stage IV Pancreatic Cancer AJCC v8
Stage II Pancreatic Cancer AJCC v8
Stage III Pancreatic Cancer AJCC v8
Unresectable Pancreatic Ductal Adenocarcinoma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: DDX5 Degrader FL118
Procedure: Magnetic Resonance Imaging

First Posted Date: 2024-01-16

Last Posted Date: 2025-01-17

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 84

Registration Number: NCT06206876

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Community-Based Physical Activity Intervention for Underserved Cancer Survivors

Not Applicable

Recruiting

Conditions: Hematopoietic and Lymphoid System Neoplasm
Malignant Solid Neoplasm

Interventions: Other: Exercise Intervention
Other: Questionnaire Administration

First Posted Date: 2024-01-16

Last Posted Date: 2024-12-04

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 200

Registration Number: NCT06206863

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy